OKYO Pharma Limited is a biotechnology company focused on developing innovative therapies for inflammatory and pain-related conditions
The company is engaged in the research and clinical development of novel drug candidates that leverage its proprietary technologies to address unmet medical needs. By targeting specific biological pathways and mechanisms, OKYO aims to create effective treatments for various diseases, including those that affect the eyes and respiratory system, ultimately improving patient outcomes and quality of life. With a commitment to advancing scientific knowledge and fostering collaboration within the healthcare community, OKYO is positioned at the forefront of therapeutic innovation.
Latest findings from OKYO Pharma's Phase 2 trial on OK-101 for dry eye disease. Significant reductions in ocular pain, improved Tear Film Break-Up Time, and symptomatic relief were observed. Statistically significant effects pave the way for Phase 3 development.
OKYO Pharma Limited (NASDAQOKYO) announced that its first drug candidate, OK-101, presently in a 240-patient phase 2 trial in patients with dry eye disease (DED) is currently showing a positive safety profile in
Gainers Orchard Therapeutics plc (NASDAQORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS.
Gainers T2 Biosystems, Inc. (NASDAQTTOO) shares rose 44.4% to $0.4003 in pre-market trading. T2 Biosystems said it issued inducement awards to four new employees.
Gainers First Wave BioPharma, Inc. (NASDAQFWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi.
